Metabolic remodelling in human heart failure

Cardiovascular Research

Volumn 90, Issue 2, 2011, Pages 251-257

  Tuunanen, Helena ^a   Knuuti, Juhani ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Heart failure; Myocardial substrate metabolism; Remodelling

Indexed keywords

ACETYL COENZYME A; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARNITINE PALMITOYLTRANSFERASE I; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FATTY ACID; GLUCOSE; INSULIN; PYRUVATE DEHYDROGENASE;

ARTICLE; CARDIOMYOPATHY; CONGESTIVE CARDIOMYOPATHY; GLUCOSE METABOLISM; HEART FAILURE; HEART MUSCLE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN RESPONSE; INSULIN SENSITIVITY; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ENERGY METABOLISM; HEART FAILURE; HUMANS; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 79955451479     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvr052     Document Type: Article

References (91)

1. Remme WJ, Swedberg K. Task Force for the Diagnosis and Treatment of Chronic Heart Failure European Society of Cardiology. Guidelines forthe diagnosis and treat-ment of chronic heart failure. Eur Heart J 2001; 22: 1527-1560. (Pubitemid 32801300)
2. Opie LH, Knuuti J. The adrenergic-fatty acid load in heart failure. J Am Coll Cardiol 2009;54:1637-1646.
3. Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS et al. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest 1996;98:2094-2099. (Pubitemid 26376298)
4. Maki M, Luotolahti M, Nuutila P, Iida H, Voipio-Pulkki LM, Ruotsalainen U et al. Glucose uptake in the chronically dysfunctional but viable myocardium. Circulation 1996;93:1658-1666. (Pubitemid 26131342)
5. Stolen KQ, Kemppainen J, Kalliokoski KK, Hallsten K, Luotolahti M, Karanko H et al. Myocardial perfusion reserve and oxidative metabolism contribute to exercise capacity in patients with dilated cardiomyopathy. J Card Fail 2004;10:132-140. (Pubitemid 38858074)
6. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in dia-betics in the Framingham population. Sixteen year follow-up study. Diabetes 1974; 23:105-111.
7. Solang L, Malmberg K, Ryden L Diabetes mellitus and congestive heartfailure. Further knowledge needed. Eur Heart J 1999;20:789-795. (Pubitemid 29240249)
8. Zoneraich S. Ischemic heart disease and diabetic cardiomyopathy. J Am Coll Cardiol 1989;14:1585-1586. (Pubitemid 19279067)
9. Witteles RM, Tang WH, Jamali AH, Chu JW, Reaven GM, Fowler MB. Insulin resist-ance in idiopathic dilated cardiomyopathy: a possible etiologic link. J Am Coll Cardiol 2004;44:78-81. (Pubitemid 38968461)
10. Ingelsson E, Sundstrom J, Arnlov J, Zethelius B, Lind L Insulin resistance and risk of congestive heart failure. JAMA 2005;294:334-341. (Pubitemid 41043777)
11. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007;116:434-448. (Pubitemid 47196549)
12. Taegtmeyer H, McNulty P, Young ME. Adaptation and maladaptation ofthe heart in diabetes: Part I: general concepts. Circulation 2002;105:1727-1733. (Pubitemid 34298619)
13. Vermes E, Ducharme A, Bourassa MG, Lessard M, White M, Tardif JC et al. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation 2003;107: 1291-1296. (Pubitemid 36314413)
14. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejec-tion fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-781. (Pubitemid 37093918)
15. Hara Y, Hamada M, Shigematsu Y, Ohtsuka T, Ogimoto A, Suzuki J et al. Effect of beta-blocker therapy in elderly patients with dilated cardiomyopathy. Circ J 2003; 67:826-829. (Pubitemid 37229218)
16. Pietila M, Malminiemi K, Huupponen R, Rouru J, Pulkki K, Pere E et al. Celiprolol aug-ments the effect of physical exercise on insulin sensitivity and serum lipid levels in chronic heart failure. Eur J Heart Fail 2000;2:81-90. (Pubitemid 30202290)
17. Podbregar M, Voga G. Effect of selective and nonselective beta-blockers on resting energy production rate and total body substrate utilization in chronic heart failure. J Card Fail 2002;8:369-378. (Pubitemid 36055737)
18. Refsgaard J, Thomsen C, Andreasen F, Gotzsche O. Carvedilol does not alter the insulin sensitivity in patients with congestive heart failure. Eur J Heart Fail 2002;4: 445-453. (Pubitemid 36564962)
19. Stroedter D, Schmidt T, Bretzel RG, Federlin K. Glucose metabolism and left ventri-cular dysfunction are normalized by insulin and islet transplantation in mild diabetes in the rat. Acta Diabetol 1995;32:235-243. (Pubitemid 26007465)
20. Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 2001;103:2668-2673. (Pubitemid 32538780)
21. Doehner W, Rauchhaus M, Ponikowski P, Godsland IF, von Haehling S, Okonko DO et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 2005;46:1019-1026. (Pubitemid 41316509)
22. Paolisso G, Tagliamonte MR, Rizzo MR, Gambardella A, Gualdiero P, Lama D et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with con-gestive heart failure secondary to mitral and/or aortic valve disease. Am J Cardiol 1999; 83:1338-1344. (Pubitemid 29205743)
23. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG et al. Obesity and the risk of heart failure. N Engl J Med 2002;347:305-313. (Pubitemid 34815352)
24. Horwich TB, Fonarow GC. The impact of obesity on survival in patients with heart failure. Heart Fail Monit 2002;3:8-14.
25. Lavie CJ, Osman AF, Milani RV, Mehra MR. Body composition and prognosis in chronic systolic heart failure: the obesity paradox. Am J Cardiol 2003;91:891-894. (Pubitemid 36363743)
26. Kistorp C, Faber J, Galatius S, Gustafsson F, Frystyk J, Flyvbjerg A et al. Plasma adipo-nectin, body mass index, and mortality in patients with chronic heart failure. Circulation 2005;112:1756-1762. (Pubitemid 41372115)
27. Allison DB, Faith MS, Heo M, Kotler DP. Hypothesis concerning the U-shaped relation between body mass index and mortality. Am J Epidemiol 1997;146:339-349. (Pubitemid 27355570)
28. Stanley WC, Recchia FA, Lopaschuk GD. Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 2005;85:1093-1129. (Pubitemid 40894649)
29. Nuutila P, Koivisto VA, Knuuti J, Ruotsalainen U, Teras M, Haaparanta M et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992;89:1767-1774.
30. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963;1:785-789.
31. Kates AM, Herrero P, Dence C, Soto P, Srinivasan M, Delano DG et al. Impact of aging on substrate metabolism by the human heart. J Am Coll Cardiol 2003;41:293-299. (Pubitemid 36092200)
32. Taegtmeyer H. Energy metabolism ofthe heart: from basic concepts to clinical appli-cations. Curr Probl Cardiol 1994;19:59-113.
33. Zaninetti D, Greco-Perotto R, Jeanrenaud B. Heart glucose transport and transpor-ters in rat heart: regulation by insulin, workload and glucose. Diabetologia 1988;31: 108-113.
34. Knuuti MJ, Maki M, Yki-Jarvinen H, Voipio-Pulkki LM, Harkonen R, Haaparanta M et al. The effect of insulin and FFA on myocardial glucose uptake. J Mol Cell Cardiol 1995;27: 1359-1367.
35. Hardy CJ, Weiss RG, Bottomley PA, Gerstenblith G. Altered myocardial high-energy phosphate metabolites in patients with dilated cardiomyopathy. Am Heart J 1991;122: 795-801.
36. Neubauer S. The failing heart\an engine out of fuel. N Engl J Med 2007;356: 1140-1151. (Pubitemid 46425598)
37. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W et al. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated car-diomyopathy. Circulation 1997;96:2190-2196. (Pubitemid 27425822)
38. Osorio JC, Stanley WC, Linke A, Castellari M, Diep QN, Panchal AR et al. Impaired myocardial fatty acid oxidation and reduced protein expression of retinoid X receptor-alpha in pacing-induced heart failure. Circulation 2002;106:606-612. (Pubitemid 34827712)
39. Recchia FA, McConnell PI, Bernstein RD, Vogel TR, Xu X, Hintze TH. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious dog. Circ Res 1998;83:969-979. (Pubitemid 28520926)
40. Nikolaidis LA, Sturzu A, Stolarski C, Elahi D, Shen YT, Shannon RP. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyo-pathy. Cardiovasc Res 2004;61:297-306. (Pubitemid 38091770)
41. Paolisso G, Gambardella A, Galzerano D, D'Amore A, Rubino P, Verza M et al. Total-body and myocardial substrate oxidation in congestive heart failure. Metabolism 1994; 43:174-179. (Pubitemid 24061849)
42. Lommi J, Kupari M, Yki-Jarvinen H. Free fatty acid kinetics and oxidation in congestive heart failure. Am J Cardiol 1998;81:45-50. (Pubitemid 28046841)
43. Norrelund H, Wiggers H, Halbirk M, Frystyk J, Flyvbjerg A, Botker HE et al. Abnorm-alities of whole body protein turnover, muscle metabolism and levels of metabolic hormones in patients with chronic heart failure. J Intern Med 2006;260:11-21. (Pubitemid 43894065)
44. Taylor M, Wallhaus TR, Degrado TR, Russell DC, Stanko P, Nickles RJ et al. An evalu-ation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in Patients with Congestive Heart Failure. J Nucl Med 2001;42:55-62. (Pubitemid 32104778)
45. Davila-Roman VG, Vedala G, Herrero P, de las Fuentes L, Rogers JG, Kelly DP et al. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyo-pathy. J Am Coll Cardiol 2002;40:271-277. (Pubitemid 34756287)
46. van den Heuvel AF, van Veldhuisen DJ, van der Wall EE, Blanksma PK, Siebelink HM, Vaalburg WM et al. Regional myocardial blood flow reserve impairment and meta-bolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardi-omyopathy. J Am Coll Cardiol 2000;35:19-28. (Pubitemid 30061254)
47. Chandler MP, Kerner J, Huang H, Vazquez E, Reszko A, Martini WZ et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxi-dation. Am J Physiol Heart Circ Physiol 2004;287:H1538-H1543. (Pubitemid 39313257)
48. Lei B, Lionetti V, Young ME, Chandler MP, d'Agostino C, Kang E et al. Paradoxical downregulation of the glucose oxidation pathway despite enhanced flux in severe heart failure. J Mol Cell Cardiol 2004;36:567-576. (Pubitemid 38469947)
49. Sack MN, Rader TA, Park S, Bastin J, McCune SA, Kelly DP. Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 1996;94: 2837-2842. (Pubitemid 26411749)
50. Razeghi P, Young ME, Alcorn JL, Moravec CS, Frazier OH, Taegtmeyer H. Metabolic gene expression in fetal and failing human heart Circulation 2001;104:2923-2931. (Pubitemid 33139104)
51. Martin MA, Gomez MA, Guillen F, Bornstein B, Campos Y, Rubio JC et al. Myocardial carnitine and carnitine palmitoyltransferase deficiencies in patients with severe heart failure. Biochim Biophys Acta 2000;1502:330-336.
52. Sabbah HN, Chandler MP, Mishima T, Suzuki G, Chaudhry P, Nass O et al. Ranolazine, a partial fatty acid oxidation (pFOX) inhibitor, improves left ventricular function in dogs with chronic heart failure. J Card Fail 2002;8:416-422. (Pubitemid 36055744)
53. Kelly DP, Strauss AW. Inherited cardiomyopathies. N Engl J Med 1994;330:913-919. (Pubitemid 24094973)
54. Bergmann SR, Herrero P, Sciacca R, Hartman JJ, Rubin PJ, Hickey KT et al. Character-ization of altered myocardial fatty acid metabolism in patients with inherited cardio-myopathy. J Inherit Metab Dis 2001;24:657-674. (Pubitemid 33130087)
55. Buchanan J, Mazumder PK, Hu P, Chakrabarti G, Roberts MW, Yun UJ et al. Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity. Endocrinology 2005;146:5341-5349. (Pubitemid 41653047)
56. Sharma S, Adrogue JV, Golfman L, Uray I, Lemm J, Youker K et al. Intramyocardial lipid accumulation in the failing human heart resembles the lipotoxic rat heart. FASEB J 2004;18:1692-1700. (Pubitemid 39463708)
57. Tuunanen H, Engblom E, Naum A, Scheinin M, Nagren K, Airaksinen J et al. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J Card Fail 2006;12:644-652. (Pubitemid 44512144)
58. Bengel FM, Permanetter B, Ungerer M, Nekolla S, Schwaiger M. Non-invasive esti-mation of myocardial efficiency using positron emission tomography and carbon-11 acetate-comparison between the normal and failing human heart. Eur J Nucl Med 2000;27:319-326. (Pubitemid 30167703)
59. Kim IS, Izawa H, Sobue T, Ishihara H, Somura F, Nishizawa T et al. Prognostic value of mechanical efficiency in ambulatory patients with idiopathic dilated cardiomyopathy in sinus rhythm. J Am Coll Cardiol 2002;39:1264-1268. (Pubitemid 34297864)
60. Stolen KQ, Kemppainen J, Kalliokoski KK, Karanko H, Toikka J, Janatuinen T et al. Myocardial perfusion reserve and peripheral endothelial function in patients with idio-pathic dilated cardiomyopathy. Am J Cardiol 2004;93:64-68. (Pubitemid 38022035)
61. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, Iida H et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000;68: 522-531.
62. Mallat Z, Philip I, Lebret M, Chatel D, Maclouf J, Tedgui A. Elevated levels of 8-iso-prostaglandin F2alpha in pericardial fluid of patients with heart failure: a poten-tial role for in vivo oxidant stress in ventricular dilatation and progression to heart failure. Circulation 1998;97:1536-1539. (Pubitemid 28186180)
63. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS et al. Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 1998;31: 1352-1356. (Pubitemid 28219127)
64. Cappola TP, Kass DA, Nelson GS, Berger RD, Rosas GO, Kobeissi ZA et al. Allopur-inol improves myocardial efficiency in patients with idiopathic dilated cardiomyopa-thy. Circulation 2001;104:2407-2411. (Pubitemid 33108372)
65. Eichhorn EJ, Heesch CM, Barnett JH, Alvarez LG, Fass SM, Grayburn PA et al. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol 1994;24:1310-1320. (Pubitemid 24331872)
66. Beanlands RS, Nahmias C, Gordon E, Coates G, deKemp R, Firnau G et al. The effects of beta(1)-blockade on oxidative metabolism and the metabolic cost of ventricular work in patients with left ventricular dysfunction: A double-blind, placebo-controlled, positron-emission tomography study. Circulation 2000;102:2070-2075.
67. Panchal AR, Stanley WC, Kerner J, Sabbah HN. Beta-receptor blockade decreases carnitine palmitoyl transferase I activity in dogs with heart failure. J Card Fail 1998; 4:121-126. (Pubitemid 28381150)
68. Wallhaus TR, Taylor M, DeGrado TR, Russell DC, Stanko P, Nickles RJ et al. Myocar-dial free fatty acid and glucose use after carvedilol treatment in patients with conges-tive heart failure. Circulation 2001;103:2441-2446. (Pubitemid 32493369)
69. Al-Hesayen A, Azevedo ER, Floras JS, Hollingshead S, Lopaschuk GD, Parker JD. Selective versus nonselective beta-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization. Eur J Heart Fail 2005;7:618-623. (Pubitemid 40732995)
70. Bottcher M, Refsgaard J, Gotzsche O, Andreasen F, Nielsen TT. Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. Am J Cardiol 2002;89:1388-1393. (Pubitemid 34607779)
71. Wiggers H, Norrelund H, Nielsen SS, Andersen NH, Nielsen-Kudsk JE, Christiansen JS et al. Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium. Am J Physiol Heart Circ Physiol 2005;289:H938-H946. (Pubitemid 41129413)
72. Halbirk M, Norrelund H, Moller N, Schmitz O, Goetzche L, Nielsen R et al. Suppres-sion of circulating free fatty acids with acipimox in chronic heart failure patients changes whole body metabolism but does not affect cardiac function. Am J Physiol Heart Circ Physiol 2010;299:H1220-H1225.
73. Tuunanen H, Engblom E, Naum A, Nagren K, Hesse B, Airaksinen KE et al. Free fatty acid depletion acutely decreases cardiac work and efficiency in cardiomyopathic heart failure. Circulation 2006;114:2130-2137. (Pubitemid 44747893)
74. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L et al. Recom-binant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopa-thy. Circulation 2004;110:955-961. (Pubitemid 39128621)
75. Belardinelli R, Purcaro A. Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardio-myopathy. Eur Heart J 2001;22:2164-2170. (Pubitemid 33139462)
76. Di Napoli P, Taccardi AA, Barsotti A. Long term cardioprotective action of trimeta-zidine and potential effect on the inflammatory process in patients with ischaemic dilated cardiomyopathy. Heart 2005;91:161-165.
77. Fragasso G, Perseghin G, De Cobelli F, Esposito A, Palloshi A, Lattuada G et al. Effects of metabolic modulation by trimetazidine on left ventricular function and phospho-creatine/adenosine triphosphate ratio in patients with heart failure. Eur Heart J 2006;27:942-948.
78. Fragasso G, Piatti Md PM, Monti L, Palloshi A, Setola E, Puccetti P et al. Short-and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy. Am Heart J 2003;146:E18.
79. Lu C, Dabrowski P, Fragasso G, Chierchia SL Effects oftrimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease. Am J Cardiol 1998;82: 898-901. (Pubitemid 28467367)
80. Rosano GM, Vitale C, Sposato B, Mercuro G, Fini M. Trimetazidine improves left ven-tricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study. Cardiovasc Diabetol 2003;2:16.
81. Vitale C, Wajngaten M, Sposato B, Gebara O, Rossini P, Fini M et al. Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease. Eur Heart J 2004;25:1814-1821. (Pubitemid 39330232)
82. Tuunanen H, Engblom E, Naum A, Nagren K, Scheinin M, Hesse B et al. Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated car-diomyopathy. Circulation 2008;118:1250-1258.
83. Fragasso G, Palloshi A, Puccetti P, Silipigni C, Rossodivita A, Pala M et al. A random-ized clinicaltrial oftrimetazidine, a partialfree fatty acid oxidation inhibitor, in patients with heart failure.JAm Coll Cardiol 2006;48:992-998. (Pubitemid 44292461)
84. El-Kady T, El-Sabban K, Gabaly M, Sabry A, Abdel-Hady S. Effectsoftrimetazidineon myo-cardial perfusion and the contractile response ofchronically dysfunctional myocardium in ischemic cardiomyopathy: a 24-month study. Am J Cardiovasc Drugs 2005;5:271-278. (Pubitemid 40994269)
85. Monti LD, Landoni C, Setola E, Galluccio E, Lucotti P, Sandoli EP et al. Myocardial insulin resistance associated with chronic hypertriglyceridemia and increased FFA levels in Type 2 diabetic patients. Am J Physiol Heart Circ Physiol 2004;287: H1225-H1231. (Pubitemid 39096670)
86. Belardinelli R, Solenghi M, Volpe L, Purcaro A. Trimetazidine improves endothelial dysfunction in chronic heart failure: an antioxidant effect Eur Heart J 2007;28: 1102-1108. (Pubitemid 47343882)
87. Lee L, Campbell R, Scheuermann-Freestone M, Taylor R, Gunaruwan P, Williams L et al. Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment. Circulation 2005;112: 3280-3288. (Pubitemid 43739373)
88. Phan TT, Shivu GN, Choudhury A, Abozguia K, Davies C, Naidoo U et al. Multi-centre experience on the use of perhexiline in chronic heart failure and refractory angina: old drug, new hope. Eur J Heart Fail 2009;11:881-886.
89. Bansal M, Chan J, Leano R, Pillans P, Horowitz J, Marwick TH. Effects of perhexiline on myocardial deformation in patients with ischaemic left ventricular dysfunction. Int J Cardiol 2010;139:107-112.
90. Schmidt-Schweda S, Holubarsch C. First clinical trial with etomoxir in patients with chronic congestive heart failure. Clin Sci (Lond) 2000;99:27-35. (Pubitemid 30479390)
91. Holubarsch CJ, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate con-gestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci (Lond) 2007;113:205-212. (Pubitemid 47237917)